A panel of clinicians from anesthesiology, surgery, nephrology, hypertension, cardiology, and pharmacology was convened to discuss pharmacologic therapeutics in the management of hypertensive crisis and perioperative hypertension. The panel discussed the advantages and limitations of currently available parenteral drugs, and assessed the potential use of fenoldopam mesylate, a drug in clinical development since 1981, and recently approved by the U.S. Food and Drug Administration (FDA). Fenoldopam is a dopamine receptor (DA1selective) agonist that is a systemic and renal vasodilator. It was concluded that fenoldopam offers significant advantages as a parenterally administered agent for the management of blood pressure in both hypertensive emergencies and in the perioperative setting.
Oparil, S., Aronson, S., Deeb, G. M., Epstein, M., Levy, J. H., Luther, R. R., … Taylor, A. (1999, July). Fenoldopam: A new parenteral antihypertensive: Consensus roundtable on the management of perioperative hypertension and hypertensive crises. American Journal of Hypertension. https://doi.org/10.1016/S0895-7061(99)00059-X